TrialPath
Prostate cancer · Miami

Prostate cancer clinical trials in Miami

20 recruiting prostate cancer studies within range of Miami. Click any trial for full eligibility criteria and contact info.

Precise Oncology Interventions in Nutrition and Training (OnPoint)

Recruiting

The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.

PhaseNA
TypeInterventional
Age18 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
▾Tap for details
Apply

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382 · Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma
Recruiting

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

PhasePhase 2
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 581 more
SponsorNational Cancer Institute (NCI)
▾Tap for details

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774 · Cancer, Metastatic, Cancer, Cancer of Pancreas
Recruiting

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Phase—
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 67 more
SponsorMassive Bio, Inc.
▾Tap for details
Apply

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

NCT01885299 · Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Recruiting

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)

Phase—
TypeObservational
AgeAny
WhereColorado Springs, Colorado, United States + 12 more
SponsorThe Radiosurgery Society
▾Tap for details
Apply

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

PhasePhase 3
TypeInterventional
Age18 Years
WhereOrange, California, United States + 287 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

NCT06392295 · Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Recruiting

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

PhasePhase 2
TypeInterventional
Age18 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
▾Tap for details
Apply

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)
Recruiting

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 121 more
SponsorExelixis
▾Tap for details
Apply

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Recruiting

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereFountain Valley, California, United States + 18 more
SponsorPathos AI, Inc.
▾Tap for details
Apply

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881 · Brain Cancer, Breast Cancer, Bladder Cancer
Recruiting

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.

Phase—
TypeObservational
Age40 Years
WhereDuarte, California, United States + 16 more
SponsorAdela, Inc
▾Tap for details
Apply

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432 · Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer
Recruiting

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

PhasePhase 1
TypeInterventional
Age18 Years
WhereBeverly Hills, California, United States + 36 more
SponsorSystImmune Inc.
▾Tap for details
Apply

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

NCT07455903 · Prostate Cancer, Localized Prostate Carcinoma
Recruiting

The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).

PhasePhase 2
TypeInterventional
Age18 Years
WhereMiami, Florida, United States
SponsorBaptist Health South Florida
▾Tap for details
Apply

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601 · Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm
Recruiting

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.

PhasePhase 1
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 32 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

Recruiting

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 99 Years
WhereDuarte, California, United States + 37 more
SponsorAstraZeneca
▾Tap for details
Apply

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

NCT07887971 · NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC
Recruiting

This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.

PhasePhase 1
TypeInterventional
Age18 Years
WhereMiami, Florida, United States + 1 more
SponsorAktis Oncology, Inc.
▾Tap for details
Apply

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Recruiting

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnchorage, Alaska, United States + 394 more
SponsorCanadian Cancer Trials Group
▾Tap for details
Apply

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

PhasePhase 2
TypeInterventional
Age18 Years
WhereGoodyear, Arizona, United States + 22 more
SponsorKyntra Bio
▾Tap for details
Apply

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Recruiting

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Phase—
TypeObservational
Age40 Years – 75 Years
WhereAnchorage, Alaska, United States + 750 more
SponsorAlliance for Clinical Trials in Oncology
▾Tap for details
Apply

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

NCT07278362 · Prostate Cancer, Hypogonadism, Male
Recruiting

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

PhasePhase 4
TypeInterventional
Age18 Years
WhereMiami, Florida, United States + 1 more
SponsorUniversity of Miami
▾Tap for details
Apply

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670 · Prostate Cancer
Recruiting

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years – 100 Years
WhereScottsdale, Arizona, United States + 92 more
SponsorNovartis Pharmaceuticals
▾Tap for details
Apply

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194 · Biliary Tract Cancer, Breast Cancer, Cervical Cancer
Recruiting

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereDenver, Colorado, United States + 5 more
SponsorModeX Therapeutics, An OPKO Health Company
▾Tap for details
Apply